Thor Medical ASA (LON:0R6Y)

United Kingdom · Delayed Price · Currency is GBP · Price in NOK

4.125

+0.040 (0.98%)

At close: Nov 10, 2026

Market Cap	138.87M +46.0%
Revenue (ttm)	124.71K +1,539.0%
Net Income	-6.32M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	4.085
Day's Range	n/a
52-Week Range	3.520 - 7.110
Beta	-0.23
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Thor Medical ASA

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2009

Employees 24

Stock Exchange London Stock Exchange

Ticker Symbol 0R6Y

Financial Performance

Financial numbers in NOK Financial Statements

News

Thor Medical ASA Earnings Call Transcript: H1 2026

AlphaOne is now operational, enabling first commercial deliveries and strong revenue visibility through NOK 850 million in sales agreements. H1 2026 saw NOK 900,000 in revenue and a negative EBITDA, but ramp-up is on track with EBITDA breakeven expected in 2027.

2 months ago - Transcripts

Thor Medical ASA Quarterly report: H1 2026

Thor Medical ASA has published its H1 2026 quarterly earnings report on August 28, 2026.

2 months ago - Filings

Thor Medical ASA Slides: H1 2026

Thor Medical ASA has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 28, 2026.

2 months ago - Filings

Thor Medical ASA Earnings Call Transcript: H2 2025

AlphaOne remains on track for completion and production ramp-up, supported by a NOK 850 million order backlog and strong market demand for alpha-emitting isotopes. The company is fully funded to reach cash-positive operations by 2027, with significant revenue potential and a growing customer base.

8 months ago - Transcripts